News

Gerald Prager, MD, Medical University of Vienna

Videos

Trifluridine/Tipiracil Plus Bevacizumab For Refractory Metastatic Colorectal Cancer

08/11/2023

At the 2023 World Congress on Gastrointestinal Cancers, Gerald Prager, MD, presents data on a trial evaluating trifluridine/tipiracil plus bevacizumab for patients with refractory metastatic colorectal cancer.

At the 2023 World Congress on...

08/11/2023

Oncology

News

Effect of HER2 Overexpression or Amplification on Resistance to Anti-EGFR Treatment Among Patients with RAS Wild-Type Metastatic Colorectal Cancer

08/10/2023

Allison Casey ;

According to a systemic review and meta-analysis, patients with HER2-positive, RAS wild-type metastatic colorectal cancer who were treated with anti-EGFR therapies were more likely to have worse progression-free survival and response than...

According to a systemic review...

08/10/2023

Oncology

News

Second-Line Avelumab Improved PFS and Disease Control Among Patients With dMMR/MSI Metastatic Colorectal Cancer

08/10/2023

Allison Casey ;

According to a phase 2 trial, avelumab had better efficacy and tolerability among patients with deficient mismatch repair and/or microsatellite instability metastatic colorectal cancer compared with standard-of-care chemotherapy.

According to a phase 2 trial,...

08/10/2023

Oncology

Akihito Kawazoe, MD, National Cancer Center East - Japan

Videos

Lenvatinib Plus Pembrolizumab Did Not Significantly Improve Survival Among Patients with Metastatic Colorectal Cancer

08/10/2023

Akihito Kawazoe , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Akihito Kawazoe, MD, shared results from the phase 3 LEAP-017 trial, evaluating lenvatinib plus pembrolizumab among previously treated patients with metastatic colorectal cancer.

At the 2023 World Congress on...

08/10/2023

Oncology

News

FDA Approval of Trifluridine and Tipiracil With Bevacizumab for Patients With Previously Treated Metastatic Colorectal Cancer

08/02/2023

Allison Casey ;

On August 2, 2023, the FDA granted approval to trifluridine and tipiracil plus bevacizumab for the treatment of patients with previously treated metastatic colorectal cancer.

On August 2, 2023, the FDA...

08/02/2023

Oncology

Kristen Ciombor, MD, Vanderbilt-Ingram Cancer Center

Videos

Checkpoint Inhibition for Patients With Colorectal Cancer and High Microsatellite Instability

08/01/2023

Kristen Ciombor , MD, MSc;

At the 2023 World Congress on Gastrointestinal Cancers, Kristen Ciombor, MD, discussed the opportunities for checkpoint inhibition among patients with colorectal cancer and high microsatellite instability.

At the 2023 World Congress on...

08/01/2023

Oncology

Yu Sunakawa, MD, St. Marianna University School of Medicine

Videos

Modified FOLFOXIRI Plus Cetuximab as the First-Line Treatment for Patients With RAS Wild-Type Metastatic Colorectal Cancer

07/28/2023

Yu Sunakawa , MD;

At the 2023 ESMO World Congress on Gastrointestinal Cancers, Yu Sunakawa, MD, presented updated survival data from the phase 2 DEEPER trial, evaluating modified(m)-FOLFOXIRI plus cetuximab vs m-FOLFOXIRI plus bevacizumab among patients with...

At the 2023 ESMO World Congress...

07/28/2023

Oncology

Federica Marmorino, MD, University of Pisa

Videos

Effect of Gut Microbiome Composition on Atezolizumab Efficacy Among Patients With Colorectal Cancer

07/28/2023

F. Marmorino ;

At the 2023 World Congress on Gastrointestinal Cancers, Federica Marmorino, MD, discusses the effect the gut microbiome composition may have on the efficacy of checkpoint inhibitors like atezolizumab for colorectal cancer.

At the 2023 World Congress on...

07/28/2023

Oncology

Rachel Purcell, PhD, University of Otago, Christchurch

Videos

Effect of Microbiome on Colorectal Cancer Tumor Microenvironment

07/13/2023

Rachel Purcell , PhD;

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, different microbes in the colorectal cancer tumor microenvironment were found to increase immune activity and potentially have an immunosuppressive effect.

According to a study presented...

07/13/2023

Oncology

Michael White, MD, MD Anderson Cancer Center

Videos

Mutational Signature Similarities and Differences Between Appendiceal Adenocarcinoma and Colorectal Cancer

07/13/2023

Michael White , MD;

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, there were distinct mutational differences noted between appendiceal adenocarcinoma and colorectal cancer.

According to a study presented...

07/13/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology